Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02065297
Other study ID # AUDIA-SAMSON HORTON TH17
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 28, 2009

Study information

Verified date May 2019
Source Centre Hospitalier Universitaire Dijon
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this open, controlled, multicentre biomedical research study is to identify new markers specifically associated with Horton's disease. This would make it possible to improve the diagnosis and management of this disease.

Participation consists in taking one or several blood samples depending on the group patients/controls.


Recruitment information / eligibility

Status Completed
Enrollment 143
Est. completion date
Est. primary completion date January 7, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

Patients

- Patients who have provided written informed consent

- Patients with national health insurance cover

- Age: 50 to 90 years

Patients with Horton' s disease :

- at the diagnosis, before any treatment

- or in remission

- or in relapse

Patients with an infectious disease :

- Bacteriologically or radiologically confirmed

- Presenting an inflammatory syndrome defined by :

- CRP = 10 mg / L

- and Fibrinogen = 4 g / L or ESR = 30 mm at H1

Patients with neoplasia ( solid tumour or hemopathy ) :

- At the diagnosis, before treatment by chemotherapy

- Presenting an inflammatory syndrome defined by:

- CRP = 10 mg / L

- and Fibrinogen = 4 g / L or ESR = 30 mm at H1

Controls :

These are healthy volunteers recruited among blood donators at Dijon CHU, voluntary hospital personnel ( nurses, doctors and secretaries ), patients at the EPHAD ( Champmaillot centre for geriatric patients ) and patients without infectious, inflammatory, or auto-immune disease ( CRP < 5mg / L ) or cancer recruited from the investigating departments of Dijon CHU. They will be matched for age and sex.

- Age: 18 - 90 years

- Patients with national health insurance cover

- who have provided written informed consent

- Absence of an inflammatory syndrome ( CRP < 5 mg / L )

Exclusion Criteria :

- Any patient who does not meet the inclusion criteria

Study Design


Intervention

Other:
1 blood sample

2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)


Locations

Country Name City State
France CHU de BESANCON Besancon
France CHU de DIJON Dijon
France CH de METZ Metz

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quantification of specific cytokines of the Th17 immune response (IL-17 A and IL-23) in the serum Up to 6 months
Primary Quantification of LTh17 by flow cytometry Up to 6 months
Primary Measurement of the activation level of genes specifically involved in Th17 response using RT-PCR on frozen mRNA Up to 6 months
Primary Measure the ability of Treg to proliferate and to synthesize IL-17 in response to different antigenic stimulations Up to 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2